Response to Comments: Pharmacogenomics Testing

This file contains summaries of public comments and contractor responses regarding the Proposed LCD DL39063 for Pharmacogenomics Testing and indicates that comments were reviewed and incorporated where applicable. The document does not itself define specific coverage indications, limitations, documentation requirements, or frequency limits; consult the final LCD DL39063 for the detailed, actionable coverage criteria.

"This document is a compilation of public comment summaries and contractor responses for LCD DL39063 (Pharmacogenomics Testing) and does not itself specify clinical coverage criteria; refer to the f..."

Sign up to see full coverage criteria, indications, and limitations.